Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
18 February 2014
Focusing on England, these two presentations describe the core economic considerations in making the most of targeted therapy. OHE’s Adrian Towse participated in a two-day workshop…
Exploring the Interdependencies of Research Funders in the UK
1 July 2014
As earlier OHE research has demonstrated, sources of funding for medical research—public, charity and private sector—are complementary, not duplicative. The three sectors also differ in their…
The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness
1 April 2014
The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen,…
Personalised Medicine and the Value of Molecular Diagnostics: Case Studies
18 December 2013
Progress in personalised medicine is slower than some had expected, partly because of the science and partly because of insufficient economic incentives, particularly for investing in…
OHE Involved in Developing New AMS Report on Stratified Medicines
15 July 2013
Professor Adrian Towse, OHE’s Director, joined Professor Sir John Bell and Professor Andrew Morris at the Science Media Centre last week to launch Realising the Potential…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
A new publication from the Office of Health Economics captures the views of thought leaders from around the world about the scientific and economic climate for…
Critical Factors Affecting Pharmaceutical R&D and the Availability of New Drugs
18 June 2013
Dr Jorge Mestre-Ferrandiz, OHE’s Director of Consulting, was a recent guest lecturer at Imperial College London. His comprehensive presentation covered the gamut of issues that influence…
19th Annual Lecture: What Constitutes Credible Evidence of Effectiveness?
4 June 2013
Since 1993, OHE has hosted an annual lecture given by an eminent economist or clinician on an important current issue. In 2012, Professor Sir Michael Rawlins…
Realising the Value of Medical Research: Health and Economic Benefits
20 March 2013
OHE’s Jon Sussex is spoke today on the value of medical research at the 2013 BioWales conference, one of the UK’s largest life sciences conferences. Celebrating…